Exclusive: Malaysia’s A-Bio invests $1.8m in pathology service provider Clinipath A biological testing process underway at a personal products lab. Photo: Bloomberg Mars Woo March 21, 2018 PremiumA-Bio, a strategic investment firm established by the Malaysian government, has invested RM7 million ($1.8 million) in Clinipath Malaysia, one of the country’s leading pathology service providers. Continue reading this story with a subscription to DealStreetAsia. Subscribe Already a subscriber? Log in Should your colleagues be reading this article too? Contact us for corporate subscriptions at email@example.com.